Search clinical trials for: bendamustine and lenalidomide

Total 271390 results

Mayo Clinic

Completed

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Refractory Multiple Myeloma

United States
University Hospital Tuebingen
Arbeitsgemeinschaft fur Internistische Onkologie; German Sarcoma Group

Completed

Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)

Sarcoma, Soft Tissue

Germany
Georgetown University
Celgene Corporation; Cephalon

Completed

Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) (Phase I BLR)

Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Lymphoma

United States
Charite University, Berlin, Germany
ribosepharm GmbH

Unknown

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

Recurrent Small Cell Lung Cancer

Germany
Lund University Hospital
Mundipharma Pte Ltd.; Roche Pharma AG; Celgene

Completed

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. (LENA-BERIT)

Mantle Cell Lymphoma

Finland, Denmark, Norway, Sweden
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Celgene Corporation

Completed

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Refractory/Relapsed Indolent Non-Hodgkin Lymphoma

United States
Fondazione Italiana Linfomi ONLUS

Completed

Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL (R2-B)

Mantle Cell Lymphoma

Italy
German CLL Study Group
Roche Pharma AG; Celgene; Mundipharma Research GmbH & Co KG

Completed

A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia (CLL2P)

Chronic Lymphocytic Leukemia

Germany
Arbeitsgemeinschaft medikamentoese Tumortherapie
Celgene Corporation

Unknown

Lenalidomide in Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

Austria
University of Wisconsin, Madison
Genentech, Inc.; Celgene Corporation

Withdrawn

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)
University of California, Davis
Novartis

Completed

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

Multiple Myeloma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Untreated Adult Acute Myeloid... and other conditions

United States
Swiss Group for Clinical Cancer Research

Completed

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

Lymphoma

Switzerland
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Lymphoma | Neurotoxicity | Therapy-related Toxicity

United States, Canada
University of Leipzig
Mundipharma Pte Ltd.; Celgene Corporation; Amgen

Unknown

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Germany
Medical University of Vienna

Not yet recruiting

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Mantle-cell Lymphoma
The Lymphoma Academic Research Organisation

Recruiting

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Marginal Zone Lymphoma

France
Meir Medical Center
Assuta Ashdod Hospital; Rabin Medical Center; Tel-Aviv Sourasky Medical Center; Ziv Medical Center

Recruiting

Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status (FLMRD)

Follicular Lymphoma

Israel
Beth Christian

Completed

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
University of Wisconsin, Madison
Genentech, Inc.; Celgene Corporation

Completed

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

Lymphoma, Non-Hodgkin | Small Lymphocytic Lymphoma | Lymphoid Leukemia

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Withdrawn

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma

United States
MD Anderson International Spain SA
Celgene Corporation

Completed

Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia (LLC-LENAR-08)

Chronic Lymphocytic Leukemia

Spain
University of Arizona
Cephalon

Completed

Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer

Ovarian Cancer

United States
University of Wisconsin, Madison
Celgene Corporation

Completed

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Hoffmann-La Roche

Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE)

Lymphoma

Korea, Republic of, United States, Spain, France, Brazil, China, Canada, Australia, Sweden, Taiwan, Italy, United Kingdom
Aptevo Therapeutics

Completed

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL)

United States, Austria, Germany, Poland, Spain
Celgene
The Lymphoma Academic Research Organisation

Active, not recruiting

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma (RELEVANCE)

Follicular Lymphoma

United States, Japan
Istituto Nazionale Tumori IRCCS - Fondazione G....

Unknown

A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma (LEBEN)

Recurrent Adult Hodgkin Lymphoma

Italy
University Hospital, Lille
Celgene Corporation

Completed

Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia (RV-WM-0426)

Waldenstrom Macroglobulinemia

France
NYU Langone Health
Cephalon

Terminated

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center

Withdrawn

Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Lymphoma | Leukemia
Massachusetts General Hospital
Dana-Farber Cancer Institute

Completed

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | B Chronic Lymphocytic Leukemia

United States
The Lymphoma Academic Research Organisation
Celgene Corporation

Active, not recruiting

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)

Follicular Lymphoma

Spain, Canada, France, Australia, Italy, Belgium, Germany, Portugal
M.D. Anderson Cancer Center
Cephalon

Terminated

Bendamustine in Acute Leukemia and MDS

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

United States
Novartis Pharmaceuticals

Completed

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, Chronic

United States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
Cephalon

Completed

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Prof. Dr. Wolfgang Hiddemann
Hoffmann-La Roche; Mundipharma Research GmbH & Co KG

Completed

First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years (GABe2016)

Indolent Non-hodgkin Lymphoma

Germany
Georg Hess, MD
Wyeth is now a wholly owned subsidiary of Pfizer; Mundipharma Pte Ltd.

Completed

Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma (BERT)

Follicular Lymphoma | Mantle Cell Lymphoma

Germany
Georgetown University
GlaxoSmithKline; Cephalon

Terminated

Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Novartis Pharmaceuticals

Terminated

Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy (A+B)

Lymphoma, Follicular

United States, Belgium, Italy, Hong Kong, Austria, Germany, Japan, Russian Federation, United Kingdom, Canada, Slovakia, Poland, Ukraine, Puerto Rico, Greece, France, Argentina
University of Washington
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Neoplasm

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

Leukemia

Israel, United States, Australia, Belarus, Brazil, Canada, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Singapore
Cephalon

Completed

Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy

Malignancy

Netherlands
Columbia University

Completed

Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) (SGN+Benda)

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma

Canada, United States
Memorial Sloan Kettering Cancer Center
Cephalon

Completed

Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma

Lymphoma | Hodgkin's Disease

United States
H. Lee Moffitt Cancer Center and Research Institute
National Comprehensive Cancer Network; Cephalon

Terminated

Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors

Brain Metastases

United States
SymBio Pharmaceuticals

Completed

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
Czech Lymphoma Study Group

Not yet recruiting

Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL (CLSGMCLPOLA)

Lymphoma, Mantle-Cell

Czechia

Search clinical trials for: bendamustine and lenalidomide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations